Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sclerosing agent works best for vascular malformations? new study aims to find out

NCT ID NCT07320430

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared the effectiveness and safety of different sclerosing agents, including ethanol, for treating low-flow vascular malformations. Seventy-five participants with trunk or extremity lesions received injections under ultrasound guidance. The goal was to see which agent achieved the highest cure rate (complete or partial devascularization) with the fewest side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ethanol and other sclerosing agents
What this could lead to
If successful, this could identify the safest and most effective sclerosing agent for treating low-flow vascular malformations, improving outcomes and reducing complications.
What could go wrong
This is a completed small study (75 people) comparing existing treatments, so results may not apply to all patients. Risks include pain, skin issues, and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with schobinger stage II, III low- flow vascular malformation. * Lesion affecting Patients trunk and extremity.. * Patient accepting the risk of the procedure and sign the detailed informed - consent, and in case of children-age less than18 years old- the consent will be signed by the parents Exclusion Criteria: * Patient with high- flow vascular malformation. * Patients with schobinger I and IV AVM. * Lesion affecting face, head, and neck. * Vascular tumours; haemangioma. * Patient with hypersensitivity to embolic agents e.g., hypersensitivity to bleomycin. * Patients with CKD and elevated serum creatinine level. * Critically ill patients Including pulmonary diseases, insufficient cardiac and hepatorenal functions, systemic infection, haemorrhagic tendency. * Patient who /or his parents don't accept the risk of our procedure and don't sign the detailed informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vascular malformation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vascular malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vascular malformation

Contacts and locations

Locations

  • Faculty of medicine Ain Shams University

    Cairo, Abbassia, 00202, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.